ArticleDrug design, development and therapy2026
From Initiation to Recovery: A Longitudinal Analysis of Polymyxin B-Induced Kidney Injury in Clinical Practice.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Prophylactic esketamine for postoperative sore throat: a meta-analysis of randomized evidence.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Response to Letter to the Editor "Methodological Considerations on the Longitudinal Analysis of Polymyxin B‑Induced Kidney Injury" [Response to Letter].Drug design, development and therapy · 2026Article
- Methodological Considerations on the Longitudinal Analysis of Polymyxin B‑Induced Kidney Injury [Letter].Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Polymyxin B (PMB) is an antibiotic used to treat severe infections, but its use is associated with nephrotoxicity. Identifying risk factors for PMB-associated nephrotoxicity is essential for improving patient outcomes. Objective: This study aimed to identify risk factors for PMB-associated nephrotoxicity and evaluate their impact on renal function recovery. Patients and methods: A retrospective analysis was conducted on patients who received PMB therapy at the Second Xiangya Hospital, Central South University, from August 2022 to August 2023. Univariable and multivariable logistic regression analyses were performed to assess risk factors for acute kidney injury (AKI) and factors influencing renal recovery. AKI was defined and staged according to the KDIGO criteria based on serum creatinine changes. Results: Of the 325 patients treated with intravenous PMB, 112 (34.5%) developed AKI. Independent risk factors for PMB-associated AKI included use of vancomycin (RR=1.398, P=0.027), use of aminoglycosides (RR=2.047, P=0.018), use of amphotericin B (RR=1.834, P=0.006), use of furosemide (>20 mg/day) (RR=1.495, P=0.004), and a higher loading dose of PMB (RR=1.004, P=0.004). The median time to AKI onset was 7 days (IQR: 3-12). Renal recovery occurred in 41.1% of AKI patients, and the use of vasoactive agents was negatively associated with recovery, likely reflecting underlying hemodynamic instability rather than a direct nephrotoxic effect (OR=0.298, P=0.013). Conclusion: Key risk factors for PMB-associated AKI included the use of vancomycin, aminoglycosides, amphotericin B, high-dose furosemide (>20 mg/day), and the loading dose of PMB. Close monitoring of serum creatinine within the first week of PMB therapy is crucial for improving outcomes. Clinicians should minimize concurrent nephrotoxic agents where feasible and prioritizing rapid hemodynamic stabilization in patients with shock to optimize renal recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.